panitumumab
Amgen Reports More Than $2B in Oncology Revenues in Q4
Sales of the firm's bispecific T-cell engager Blincyto increased more than 50 percent from the fourth quarter of 2023 to 2024.
Amgen's Lumakras, Vectibix Net FDA Approval in KRAS G12C-Mutant Colorectal Cancer
The FDA also approved Qiagen's Therascreen KRAS RGQ PCR kit as a companion diagnostic to identify KRAS G12C-mutant patients.
Amgen Sees Strong Growth for Precision Oncology Drugs in Q3
Sales for Lumakras and Blincyto in particular soared during the third quarter as the firm's overall revenues climbed 23 percent year over year.
The firm's bispecific T-cell engager Blincyto and KRAS inhibitor Lumakras each provided double-digit sales growth in Q2.
Amgen's Lumakras Reports Double-Digit Sales Growth in Q1
The KRAS inhibitor recorded $82 million in sales in Q1 2024, up 11 percent compared to $74 million during the year-ago period.
Feb 7, 2024
Oct 31, 2023
Jun 1, 2023